Lorazepam

Introduction Overview

Generic Name

lorazepam

Brand Name

Ativan, Lorazepam Intensol, Loreev XR

Dosage Form

oral capsule, extended release (1 mg; 1.5 mg; 2 mg; 3 mg), oral concentrate (2 mg/mL), oral tablet (0.5 mg; 1 mg; 2 mg)

Drug Class

Benzodiazepine anticonvulsants, Benzodiazepines, Miscellaneous antiemetics

Pharmacokinetics

Absorption:
Lorazepam is well-absorbed from the gastrointestinal tract following oral administration, with peak plasma concentrations generally achieved within 1 to 6 hours depending on the dosage form. Bioavailability is high, approaching 90%, indicating minimal first-pass metabolism. The extended-release formulation releases the drug more slowly, prolonging the time to peak concentration and maintaining therapeutic plasma levels over a longer period. Factors such as food intake have minimal effect on its absorption, making lorazepam flexible for dosing relative to meals. Clinical studies confirm consistent absorption profiles in both healthy adults and elderly patients, though slower gastric emptying in geriatric populations can modestly delay peak effects.

Distribution:
Lorazepam exhibits a moderate volume of distribution (approximately 1.3 to 2.5 L/kg), reflecting distribution into body tissues including the central nervous system where its pharmacological effect is exerted. It is approximately 85-90% bound to plasma proteins, primarily albumin, which is critical in limiting free active drug concentration and potential drug interactions. Lorazepam readily crosses the blood-brain barrier due to its lipophilic nature, accounting for its rapid onset of action concerning anxiolytic and sedative effects. In addition, lorazepam crosses the placenta and is excreted in breast milk, considerations important in pregnancy and lactation.

Metabolism:
Lorazepam is extensively metabolized in the liver primarily via conjugation to an inactive lorazepam-glucuronide conjugate through phase II metabolism catalyzed by UDP-glucuronosyltransferases (UGT). Unlike other benzodiazepines, it undergoes minimal phase I oxidative metabolism by cytochrome P450 enzymes, leading to fewer clinically significant drug interactions and a more predictable metabolic profile especially in patients with compromised hepatic function. This conjugation pathway results in inactive metabolites that are pharmacologically silent, contributing to lorazepam’s relatively safe pharmacokinetic profile. The metabolism is not significantly altered by age but can be affected by severe hepatic impairment.

Elimination:
Lorazepam and its metabolites are primarily eliminated renally, with approximately 90% excreted in urine, largely as lorazepam glucuronide. The elimination half-life ranges from 12 to 16 hours in healthy adults, providing suitable duration for anxiolytic and hypnotic therapy without excessive accumulation with typical dosing regimens. In elderly or debilitated patients, the half-life may be prolonged due to decreased clearance, necessitating cautious dosing and monitoring. Renal impairment may lead to accumulation of conjugated metabolites, but lorazepam itself is usually not retained. The relatively predictable elimination profile supports its favorable tolerability and safety for clinical use, including in populations such as the elderly.

Dosage Forms

Available Dosage Forms:
- Oral extended-release capsules: 1 mg, 1.5 mg, 2 mg, 3 mg
- Oral concentrate (liquid solution): 2 mg/mL
- Oral tablets: 0.5 mg, 1 mg, 2 mg

Dosages for Adults and Adolescents:
- Anxiety disorders: Initial dosing typically starts at 2 to 3 mg per day, divided into 2 to 3 doses. Maintenance dosage generally ranges from 1 to 2 mg taken 2 to 3 times daily. Dose titration should be gradual to minimize adverse effects.
- Insomnia caused by anxiety or temporary stress: 2 to 4 mg orally once daily at bedtime.
- For adult long-term treatment, clinical studies have not established efficacy beyond 4 months; use extended durations with caution.

Specific Patient Populations:
- Geriatric or debilitated patients: Recommended to start at a lower initial dose of 1 to 2 mg per day, administered in divided doses, due to increased sensitivity and slower drug clearance.
- Pediatric patients 12 years or older: Anxiety treatment initiated at 2 to 3 mg per day divided into 2 to 3 doses; maintenance doses generally range from 1 to 2 mg taken 2 to 3 times daily. Insomnia dosing aligns with adult recommendations, 2 to 4 mg at bedtime. Dosage increases should be gradual with careful monitoring.
- The extended-release capsule is intended for adults only and must be swallowed whole or the contents mixed with applesauce for patients unable to swallow capsules intact.
- The liquid concentrate should be measured with the provided dosing device and can be diluted with water, juice, soda, or semi-solid foods prior to administration.

Mechanism Of Action

Lorazepam functions as a benzodiazepine, exerting its therapeutic effects primarily through potentiation of gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the central nervous system. At the molecular level, lorazepam binds with high affinity to specific benzodiazepine binding sites located on the GABA_A receptor complex. This binding enhances GABA-induced chloride ion influx, leading to hyperpolarization of neuronal membranes and a reduction in neuronal excitability.

At the cellular level, lorazepam allosterically modulates GABA_A receptors, increasing the frequency of chloride channel opening events when GABA is present, thereby amplifying inhibitory synaptic transmission. This augmentation of GABAergic neurotransmission results in anxiolytic, sedative, hypnotic, muscle relaxant, and anticonvulsant effects. The drug preferentially targets high-affinity receptor subtypes containing specific α-subunits that mediate anxiolysis and sedation.

Biochemically, lorazepam’s enhancement of GABAergic tone stabilizes neuronal firing and suppresses abnormal excitatory circuits, which accounts for its efficacy in anxiety disorders, insomnia, and seizure control. Unlike some other benzodiazepines metabolized extensively by oxidative pathways, lorazepam’s metabolism via conjugation does not produce active metabolites, contributing to a more predictable pharmacodynamic profile.

Clinically, the rapid onset and intermediate half-life of lorazepam support its use for short- to intermediate-term management of anxiety and insomnia. Comparative studies show lorazepam shares similar mechanisms with other benzodiazepines such as diazepam and alprazolam, but distinct pharmacokinetic properties influence its clinical use. Research reveals lorazepam’s favorable safety margin in elderly and impaired hepatic patients due to reduced reliance on cytochrome P450 metabolism. Ongoing clinical trials continue to evaluate lorazepam’s efficacy in adjunctive management of agitation during alcohol withdrawal and chemotherapy-induced nausea.

Pharmacological Actions

Enhancement of GABAergic neurotransmission leading to anxiolytic effects
Sedative and hypnotic properties aiding in the treatment of insomnia
Anticonvulsant activity by stabilizing neuronal firing rates and preventing seizure propagation
Muscle relaxant effects through central nervous system depression
Antiemetic effects useful in controlling nausea and vomiting associated with cancer treatments
Reduction of agitation and delirium in alcohol withdrawal syndrome
Intermediate duration of action providing a balance between efficacy and safety
Minimal active metabolites leading to predictable pharmacokinetics
High affinity binding to benzodiazepine receptor sites on GABA_A receptors
Central nervous system depressant actions without significant respiratory depression at therapeutic doses when used alone
Modulation of limbic and cortical circuits implicated in anxiety and mood regulation
Reduced potential for drug interactions compared to benzodiazepines metabolized by cytochrome P450 enzymes
Rapid onset of action enabling timely relief of acute anxiety symptoms
Dose-dependent effects with titration guidelines to minimize adverse events

Therapeutic Or Clinical Uses

Management of anxiety disorders in adults and pediatric patients aged 12 years and older
Short-term treatment of insomnia related to anxiety or transient situational stress
Control of agitation and anxiety associated with acute alcohol withdrawal
Adjunctive treatment for nausea and vomiting during chemotherapy
Sedation prior to medical procedures when oral administration is feasible
Management of status epilepticus when used in injectable formulations (though not detailed here)
Reduction of preoperative anxiety in adults
Supportive therapy in psychiatric conditions with acute agitation
Treatment of anxiety symptoms in depressive disorders as adjunctive therapy
Use in elderly patients at adjusted doses for anxiety and insomnia management
Symptomatic relief in panic disorders off-label with clinical discretion
Temporary anxiolysis during stressful clinical settings
For debilitated or medically compromised patients, using cautiously under supervision
Treatment in pediatric patients for anxiety with careful dose adjustment
Investigated for off-label uses in procedural sedation and delirium management

Side Or Adverse Effects

Drowsiness, sedation, and excessive tiredness especially during initial treatment or dose escalation
Dizziness and unsteadiness contributing to increased risk of falls and injuries, particularly in elderly patients
Weakness and fatigue
Confusion, cognitive impairment, and difficulty concentrating
Paradoxical reactions such as agitation, excitability, aggressiveness, or hallucinations
Respiratory depression and slowed breathing, especially if combined with opioids or alcohol
Hypotension in some patients
Withdrawal symptoms including anxiety, tremors, seizures, and muscle spasms on abrupt discontinuation
Dependence and potential for misuse or addiction with prolonged use
Changes in mood or behavior, such as depression or suicidal ideation
Allergic reactions including hives, swelling, and difficulty breathing
Gastrointestinal disturbances such as nausea or constipation
Visual disturbances including blurred vision
Jaundice and dark urine indicating possible liver dysfunction
Prolonged sedation in elderly or debilitated individuals leading to impaired daytime functioning

Precautions

Use caution in patients with respiratory disorders such as asthma, COPD, or sleep apnea due to potential respiratory depression
Assess history of substance abuse or addiction prior to prescribing due to habit-forming potential
Gradually taper lorazepam to avoid life-threatening withdrawal symptoms after long-term use
Avoid abrupt discontinuation to prevent seizures and severe withdrawal syndromes
Use with caution in patients with depression, psychosis, or suicidal ideation due to potential mood alterations
Monitor liver and kidney function regularly during prolonged therapy
Avoid use during pregnancy due to risk of birth defects and neonatal withdrawal syndrome
Do not breastfeed while using lorazepam; monitor infants for sedation and feeding difficulties if exposed
Avoid concomitant use with other central nervous system depressants without medical supervision
Advise patients to avoid alcohol consumption to reduce risk of adverse effects and overdose
Use lower doses in elderly or debilitated patients due to increased sensitivity
Educate patients about the risks of dependence and importance of adherence to prescribed dosing
Caution when performing hazardous tasks such as driving until drug effects are known
Evaluate for contraindications such as narrow-angle glaucoma or known benzodiazepine hypersensitivity before initiation
Regularly assess mental status and cognitive function during therapy

Warnings

Lorazepam may cause respiratory depression which can be fatal, especially when combined with opioids, alcohol, or other CNS depressants
There is a significant risk of misuse, addiction, overdose, and death with lorazepam; it should be kept out of reach of others especially those with drug abuse history
Do not stop lorazepam abruptly after prolonged use to avoid potentially life-threatening withdrawal symptoms
Withdrawal symptoms can persist for up to 12 months or longer post discontinuation in some cases
Use during pregnancy is contraindicated due to potential for birth defects and neonatal withdrawal syndrome requiring prolonged medical care
Avoid use in patients with narrow-angle glaucoma, severe respiratory insufficiency, or myasthenia gravis
Patients should be monitored for unusual mood or behavioral changes including depression, hallucinations, aggression, or suicidal thoughts
Concomitant use with other sedatives or CNS depressants increases risk of life-threatening adverse effects
Consider the potential for cognitive impairment and falls, especially in the elderly
Lorazepam can cause severe allergy-like reactions including difficulty breathing and swelling of the face or throat
Overdose can be fatal, particularly when combined with alcohol or other respiratory depressants
Safety and efficacy for long-term use beyond 4 months have not been established; prolonged treatment requires monitoring
Lorazepam must be used only by the individual for whom it is prescribed and never shared
Patients should be counseled regarding the legal and health consequences of misuse and diversion
Emergency medical attention is required in case of symptoms such as severe drowsiness, confusion, or respiratory distress

Contraindication

Narrow-angle glaucoma
Known allergy or hypersensitivity to lorazepam or other benzodiazepines such as alprazolam, diazepam, clonazepam, and others
Severe respiratory insufficiency or respiratory depression
Myasthenia gravis
Pregnancy due to teratogenicity and neonatal withdrawal risks
Use caution or avoid in patients with acute intoxication with alcohol, CNS depressants, or opioids
Severe hepatic impairment without careful monitoring
History of benzodiazepine or substance abuse unless under strict medical supervision
Use in patients with syndrome of sleep apnea or severe pulmonary compromise without specialist evaluation
Concurrent use with potent respiratory depressants without emergency support measures
Patients unable to comply with prescribed dosing or monitoring protocols
Concurrent use of medications contraindicated due to pharmacodynamic interactions
Known hypersensitivity to preservatives or excipients contained in lorazepam injectable or concentrate preparations
Use in neonates or infants unless specifically indicated and monitored
Use in elderly with severe debilitation without dose adjustment and clinical oversight

Drug Interactions

Additive CNS depressant effects when combined with opioids, alcohol, barbiturates, or other benzodiazepines leading to increased risk of sedation, respiratory depression, coma, or death
Interaction with valproate, which can increase lorazepam plasma levels and pharmacodynamic effects
Probenecid may increase lorazepam levels by altering its metabolism and clearance
Potential interaction with aminophylline and theophylline, possibly reducing lorazepam’s sedative effects
Concurrent use with other psychotropic medications such as antipsychotics or antidepressants may potentiate CNS effects or mood alterations
Drugs containing antihistamines (used as sleep aids, allergy, or cold medications) can increase sedation when taken with lorazepam
Medications that impair hepatic conjugation pathways might theoretically alter lorazepam metabolism, though minimal CYP450 involvement limits many common interactions
Cimetidine or other inhibitors of conjugation enzymes may increase lorazepam plasma concentrations
Carbamazepine and phenytoin may decrease lorazepam efficacy via enzyme induction
Potential interaction with digoxin leading to altered digoxin levels in some case reports
Concomitant use with muscle relaxants can enhance muscle weakness and sedation
Medications affecting plasma protein binding may alter free lorazepam levels
Caution advised when combining with drugs that prolong QT interval as benzodiazepines can cause CNS depression that may complicate cardiovascular risk
Interactions with antacids are minimal, but timing of administration may optimize absorption
Herbal supplements such as kava kava, valerian, or St. John's wort may increase sedation or alter benzodiazepine effects

Preparations Of The Drug

Ativan: oral tablet and injectable forms of lorazepam for anxiety and sedation
Lorazepam Intensol: oral concentrate solution for precise dosing particularly in patients with swallowing difficulties
Loreev XR: extended-release oral capsules designed for once-daily dosing to provide prolonged anxiolytic effects
Ativan Injection: parenteral formulations for management of status epilepticus and procedural sedation (though not detailed here)
Lorazepam Oral Concentrate: alcohol-free liquid formulation facilitating dose titration and administration in pediatric and geriatric patients
Lorazepam generic tablets in multiple strengths (0.5 mg, 1 mg, 2 mg) widely available
Compounded formulations in specialized settings for customized dosing when commercial products are unsuitable
Packaging with child-resistant caps and measuring devices for liquid forms to enhance safety
Provision of patient information leaflets and medication guides emphasizing safe use and avoidance of misuse
Supply stability: oral tablets stored at room temperature; liquid concentrate refrigerated and discarded after 90 days
Extended-release capsules should be swallowed whole or contents mixed with food without crushing
Availability in various dosage strengths permits individualized therapy across diverse patient populations
Manufactured under rigorous quality control standards complying with FDA approval requirements
Commercial preparations include preservatives and excipients to maintain drug stability and palatability
Pricing and coupons often available to enhance patient access and adherence